- Fecal microbiota transplantation showed noninferiority to vancomycin therapy in treating primary Clostridioides difficile infection.
- The FMT group had higher clinical cure rates and lower disease recurrence compared to the vancomycin group.
- The trial highlighted potential advantages of FMT over first-line antibiotic therapy, including reduced antibiotic use and minimal invasiveness.
- Safety profile and mortality outcomes were similar between the FMT and vancomycin groups, with no treatment-related adverse events.
- The study emphasizes the importance of a healthy gut microbiome and supports the paradigm shift toward microbiome restoration as first-line therapy for Clostridioides difficile infection.
Source: Annals of Internal Medicine and Editorial